Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic autoreactive T cells are T lymphocytes that mistakenly recognize and react against self-antigens, leading to tissue damage and the development or perpetuation of autoimmune diseases. They arise due to failures in central and peripheral tolerance mechanisms and mediate tissue destruction through direct cytotoxicity or by orchestrating inflammatory responses. These cells are implicated in a wide range of autoimmune disorders and represent a key therapeutic target for modulating disease progression.
Targeting T cell activation, proliferation, or effector function; inducing T cell apoptosis; promoting T cell tolerance; modulating cytokine signaling
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic Autoreactive T Cell.